Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-30 @ 2:03 AM
Study NCT ID:
NCT07466303
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-12
First Post:
2026-02-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Sponsor:
Xijing Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-03-25
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-02-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-04-01
Completion Date Type:
ESTIMATED
First Submit Date:
2026-02-23
First Submit QC Date:
None
Study First Post Date:
2026-03-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-03-11
Last Update Post Date:
2026-03-12
Last Update Post Date Type:
ACTUAL